SR 120819A

Drug Profile

SR 120819A

Latest Information Update: 11 Aug 1998

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antihypertensives; Peptides
  • Mechanism of Action Neuropeptide Y receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 11 Aug 1998 No-Development-Reported for Cardiovascular disorders in USA (PO)
  • 11 Aug 1998 No-Development-Reported for Cardiovascular disorders in France (PO)
  • 30 Aug 1996 Preclinical development for Cardiovascular disorders in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top